Argos Therapeutics, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, revenue was $69,693 against $488,643 a year ago. Operating loss was $8,075,600 against $12,065,020 a year ago. Net loss was $8,538,611 against $12,606,245 a year ago. Net loss per share, basic and diluted was $0.21 against $0.48 a year ago. Interest income was $8,881 compared to $2,237 a year ago. For the six months, revenue was $174,952 against $635,072 a year ago. Operating loss was $52,059,702 against $24,395,591 a year ago. Net loss was $32,618,690 against $25,426,433 a year ago. Net loss per share, basic and diluted was $0.79 against $1.04 a year ago. Interest income was $39,458 compared to $3,813 a year ago. The decrease in revenue for the first half of 2017 compared with the first half of 2016 resulted from lower reimbursement under the Company’s contract with the NIH and NIAID primarily related to the achievement of certain specified development milestones under the Company’s AGS-004 program during 2016.